CN1101680C - 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 - Google Patents

噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 Download PDF

Info

Publication number
CN1101680C
CN1101680C CN96196835A CN96196835A CN1101680C CN 1101680 C CN1101680 C CN 1101680C CN 96196835 A CN96196835 A CN 96196835A CN 96196835 A CN96196835 A CN 96196835A CN 1101680 C CN1101680 C CN 1101680C
Authority
CN
China
Prior art keywords
apolipoprotein
compound
content
day
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96196835A
Other languages
English (en)
Chinese (zh)
Other versions
CN1195989A (zh
Inventor
H·肯彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1195989A publication Critical patent/CN1195989A/zh
Application granted granted Critical
Publication of CN1101680C publication Critical patent/CN1101680C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN96196835A 1995-09-09 1996-08-30 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 Expired - Fee Related CN1101680C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
EP95114163.9 1995-09-09

Publications (2)

Publication Number Publication Date
CN1195989A CN1195989A (zh) 1998-10-14
CN1101680C true CN1101680C (zh) 2003-02-19

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96196835A Expired - Fee Related CN1101680C (zh) 1995-09-09 1996-08-30 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途

Country Status (14)

Country Link
US (1) US5854238A (enExample)
EP (1) EP0853480B1 (enExample)
JP (1) JPH11512107A (enExample)
KR (1) KR19990044460A (enExample)
CN (1) CN1101680C (enExample)
AT (1) ATE230600T1 (enExample)
AU (1) AU725249B2 (enExample)
BR (1) BR9610390A (enExample)
CA (1) CA2230477A1 (enExample)
DE (1) DE69625696T2 (enExample)
DK (1) DK0853480T3 (enExample)
ES (1) ES2188783T3 (enExample)
TR (1) TR199800406T1 (enExample)
WO (1) WO1997009048A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
WO2003024441A1 (en) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Novel use of tricyclic compound
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3177147A4 (en) 2014-08-08 2018-01-24 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
JP2021527136A (ja) 2018-06-13 2021-10-11 ディブリー・アーゲー 縮合トリアゼピン誘導体の調製及びｂｅｔ阻害剤としてのその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (enExample) * 1974-01-08 1975-08-08

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives

Also Published As

Publication number Publication date
US5854238A (en) 1998-12-29
KR19990044460A (ko) 1999-06-25
EP0853480B1 (en) 2003-01-08
WO1997009048A1 (en) 1997-03-13
JPH11512107A (ja) 1999-10-19
CA2230477A1 (en) 1997-03-13
DK0853480T3 (da) 2003-05-05
AU6930396A (en) 1997-03-27
BR9610390A (pt) 1999-07-06
MX9801753A (es) 1998-08-30
TR199800406T1 (en) 1998-05-21
AU725249B2 (en) 2000-10-12
ATE230600T1 (de) 2003-01-15
ES2188783T3 (es) 2003-07-01
DE69625696T2 (de) 2003-10-16
EP0853480A1 (en) 1998-07-22
CN1195989A (zh) 1998-10-14
DE69625696D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
CN1101680C (zh) 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途
US6562869B1 (en) Nutritional supplement for increased energy and stamina
US6479069B1 (en) Nutritional supplement for increased energy and stamina
US5773473A (en) Creatine supplement
US5654001A (en) Dietary lipid digestion-absorption inhibitory agents and ingesta
EP1014968B1 (en) NARINGIN AND NARINGENIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR
JP4699901B2 (ja) 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質
AU2008269728B2 (en) Improving memory in subjects with mini-mental state examination of 24-26
Orthen-Gambill et al. Differential effects of amphetamine and fenfluramine on dietary self-selection in rats
HUT52396A (en) Therapeutic combination compositions and their use as antineoplastics
JPH07507569A (ja) ヒトの窒素保持の促進方法
US6852870B2 (en) Omega-3 fatty acids in the treatment of depression
US4452815A (en) Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) d-Fenfluramine for modifying feeding behavior
US6265391B1 (en) Method for preventing peripheral nerve damage
JP2001233776A (ja) 学習・記憶能低下改善剤およびその用途
Fantino et al. Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour
GB2180747A (en) Tryptophan composition for treatment of obesity
EA002177B1 (ru) Композиция для подавления симптомов абстиненции и тяги к алкоголю у алкоголиков и профилактики злоупотребления алкоголем у здоровых людей
AU666157B2 (en) Body tissue omega-3 fatty-acid-augmenting agent and nutrient composition containing the same
US5627152A (en) Method for increasing bodyweight
JP3020111B2 (ja) 体脂肪蓄積低減剤
US5093371A (en) Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
MXPA98001753A (en) Use of a thenotriazolodiazepine to increase apolipoprotein levels
KR20250088578A (ko) 베타-아드레날린 작용제 및 무스카린 길항제 조성물 및 사용 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee